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Abstract. Purine analogs modified in the 5-membered ring have been synthesized and examined for 
antibacterial activity against Mycobacterium tuberculosis H37Rv in vitro employing the microplate 
alamar blue assay (MABA). The 9-deaza analogs were only found to be weak inhibitors, but the 8-
aza-, 7-deaza- and 8-aza-7-deazapurine analogs studied displayed excellent antimycobacterial 
activities, some even substantially better than the parent purine. In the 7-deazapurine series, MIC 
values between 0.08 and 0.35 µM, values comparable or better than the reference drugs used in the 
study (MIC rifampicin 0.09 µM, MIC isoniazid 0.28 µM and MIC PA-824 0.44 µM). The five most 
active compounds were also examined against a panel of drug-resistant Mtb strain, and they all 
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retained their activity. The compounds examined were significantly less active against M. 
tuberculosis in a state of non-replicating persistence (NRP). MIC in the low-oxygen-recovery assay 
(LORA) ≥ 60 µM. The 7-deazapurines were somewhat more toxic towards mammalian cells, but 
still the selectivity indexes were excellent. The non-purine analogs exhibit a selective 
antimycobacterial activity. They were essentially inactive against Staphylococcus aureus and 
Escherichia coli. 
Introduction 
We have previously reported that certain 6,9-disubstituted purines are potent inhibitors of 
Mycobacterium tuberculosis (Mtb) in vitro.1 These antimycobacterial purines display several 
properties which make them highly interesting as potential drugs against tuberculosis. These are 
high selectivity towards Mtb compared to other microorganisms, activity against several drug 
resistant strains of Mtb, generally low toxicity towards mammalian cells, and ability to affect Mtb 
inside macrophages. Figure 1 summarizes the current SAR knowledge as well as the structures of 
some of the most active compounds in this series. 
(Fig. 1) 
Tuberculosis (TB) still claims ca. 2 million deaths pr. year worldwide and resistance to existing 
drugs is a growing problem. Thus there is an urgent need for novel drugs for the treatment of TB. 
Agents that reduce the duration and complexity of the current therapy would have a major impact 
on the overall cure rate.2 After exploring SAR of intact purines (Fig. 1), we now focus on non-
purine analogs of compounds 1.3 Certain pyrimidine analogs (general structure B, Fig. 1) display 
activity comparable with the parent purine,3b,3d but simple imidazole analogs (general structure C, 
Fig. 1) are only moderately active.3c Herein we report the synthesis and antimycobacterial activities 
for purine analogs modified in the 5-membered ring (general structure D, Fig. 1).  
Chemistry 
The 8-azapurine 5 was readily available from the pyrimidine 2 as shown in Scheme 1. The synthesis 
of 7-deaza-8-azapurine 6 (Fig. 2) has been published by us before.3a 
(Scheme 1) 
(Fig. 2) 
In contrast with what has been reported for alkylation of the 7-deazapurine 7a,4,5 the benzylation 
shown in Scheme 2 went to completion at ambient temperature, and was reasonably regioselective. 
Compound 8a was isolated in 81% and only minor amounts of more polar products (not isolated) 
were observed. Compound 8b was prepared in high yield from the corresponding dichloro-7-
deazapurine 7b. Compounds 9a – d were synthesized by Stille couplings on the chlorides 8. 
Reactions on the dichloride 8b were conducted at milder conditions in order to achieve complete 
regioselectivity. Finally the methoxy compound 9e was formed by exchange of the chloride in 
compound 9c. This is analogous with the previously reported synthesis of the 2-methoxypurine 1e 
(Fig. 1).1f 
(Scheme 2) 
9-Alkyl-9-deazapurines have been synthesized by time-consuming construction of the bicyclic ring 
system via pyrroles6 or pyrimidines,7 and alkyl- or acyl substituents have been introduced at C-9 in 
6-oxo-9-deazapurines be Friedel-Craft alkylation or acylation, but the yields are generally quite 
modest.8 Instead, we evaluated several routes for the synthesis of our target 9-deazapurines 16 and 
17 (Scheme 3), starting from 6-chloro-9-deazapurine (4-chloropyrrolo[3,2-d]pyrimidine) (10). The 
4,7-dihalopyrrolo[3,2-d]pyrimidine 13a were available be N-methylation and halogenation of 
compound 10. Attempts to introduce the p-methoxybenzyl substituent at C-9 by Negishi couplings 
on the halide 13a or the corresponding 7-iodo compound (not shown), met with little success. 9-
Deazapurine can be lithiated at C-9 by metal-halogen exchange and the lithiated species may react 
with for instance imines7b,9 or amides.6c However, attempts to introduce the desired C-9 substituent 
by lithiation of compound 13a followed by reaction with p-methoxybenzyl halides failed. This was 
in part due to migration of lithium to C-8 before reaction with the alkyl halide. Also reactions 
between lithiated 13a and anisaldehyde, the corresponding Weinreb amide, or benzoyl chloride 
turned out to be sluggish reactions. In our hands, the best route to the target molecule 17 is the one 
shown in Scheme 3. Lithiated 13a was trapped with DMF to give the aldehyde 14a in a high yield. 
Compound 14a was subsequently reacted with p-methoxyphenylmagnesium bromide. The 
secondary alcohol thus formed turned out to be difficult to isolate in pure form, but the adduct was 
instead subjected to in situ Oppenaur oxidation by benzaldehyde in the presence of LiCl10 to give 
the ketone 15a. After introduction of the furyl group by a Stille coupling on the chloride 15a, 
ketone 16a was reduced to the target 17 under Wolff-Kishner conditions. Several other reduction 
methods were unsuccessful for this transformation.  
Silyloxymethyl chlorides have been developed as reagents for N-11 and O-protection,12 and the 
protected compounds can be cleaved when treated with fluoride ions under milder conditions than 
normally required to cleave the analogous SEM-protected derivatives. The only commercially 
available of these reagents is (triisopropylsilyloxy)methyl chloride (TOM-Cl),13 and we chose the 
TOM group as N-protection group in the synthesis of target compound 16c. The N-protected ketone 
16b was synthesized as described for compound 16a above, and the protection group was 
conveniently removed by KF in methanol. The protection group was not compatible with the harsh 
conditions required in a Wolff-Kishner reduction, nor was the reduction of the carbonyl group 
compound 16c successful. However, the 9-deazapurines 16a, 16c and 17 all turned out to be far less 
active as antimycobacterial compounds compared to the parent purine and the other non-purine 
analogs reported herein (see below), and no further attempts were made to synthesize an analog of 
compound 17 with a free NH-group.  
(Scheme 3) 
Biological evaluation 
The target compounds 5, 6, 9a – 9e, 16a, 16c and 17 were screened for activity against M. 
tuberculosis H37Rv (ATCC #27294) in the microplate alamar blue assay (MABA)14 and the MIC 
values are given in Table 1. The previously synthesized purines 1a and 1b were included for 
comparison. The substituents are defined in Fig. 1, and the detailed structures can be found in Fig. 2 
and Schemes 1 – 3. 
(Table 1) 
The deazapurines 16 and 17 were only weak inhibitors of antimycobacterial growth (MIC > 90 
µM). The low activities found discouraged us from synthesis of more compounds in this series as 
described above, and no further examination of antimycobacterial activities was done for these 
substances. 
The 8-azapurine 5 and the 8-aza-7-deazapurine 6 were slightly less active than the parent purine 1a, 
showing that the purine C-8 may be exchanged with a nitrogen without a significant loss of activity. 
However, the most intriguing results were found for the 7-deazapurines 9. Compound 9a was ca. 8 
times more active than the parent purine 1a. The thienyl derivative 9b appeared to be a slightly 
weaker inhibitor than the furyl derivative 9a. The same tendency has been observed in the purine 
series before.1 In our study of the purines, we have generally seen that antimycobacterial activity is 
substantially increased when chlorine is introduced in the 2-position,1 and compounds 9c and 9d 
were the among the most active in this series. The values were in the same range as for the drug 
rifampicin and better than for isoniazid or the promising drug candidate PA-824.15 
In case of tuberculosis, a sub-population of the bacteria isolate in a state of non-replicating 
persistence (NRP). NRP is considered to be an important factor contributing to the long treatment 
duration (≥6 months required). Hence we wanted to investigate if the antimycobacterial purines and 
non-purine analogs described herein also could affect Mtb in NRP. Compounds 1a, 1b, 5, 6 and 9a 
– 9e were thus tested in the low-oxygen-recovery assay (LORA)16 (Table 1). Unfortunately, as also 
seen for many known antituberculosis drugs16 including izoniazid, the compounds were not found 
to be very active in this assay. Interestingly, it seems likely that the thienyl substituent results in 
somewhat more active compounds, and that the chloride is not beneficial for activity in the LORA. 
The best inhibitor identified in this assay was the thienyl-7-deazapurine 9b (MIC 60 µM). 
The antimycobacterial purine analogs 5, 6 and 9a – 9e were examined for toxicity against 
mammalian cells (VERO cells), and low EC50 values were found (Table 1). All deazapurines 9 were 
more toxic towards VERO cells than compounds 1, 5 and 6, but the selectivity indexes (SI) were 
still very good for these antimycobacterial compounds. For the best inhibitor of Mtb growth, 
compound 9c, the SI was found to be > 1000. 
The five most active deazapurines (9a – 9e) as well as the parent purine 1b were examined against a 
panel of Mtb strains resistant to currently used anti-TB drugs; rifampicin (RMP), isoniazid (INH), 
streptomycin (SM), kanamycin (KM) and clofazimine (CLF) (Table 2). All compounds examined 
retained their activity against all the drug resistant strains applied in this study. 
(Table 2) 
In accordance with previous findings on the structurally related purines,1 the non-purine analogs 
exhibit a selective antimycobacterial activity. Compounds 5, 6, 9a, 9c, 16a, 16c and 17 were tested 
against Staphylococcus aureus and Escherichia coli and were found to be essentially inactive (all 
MICs > 32 µg/mL; >90 µM). Even though the mode of action for our purines and non-purine 
analogs is not known, the lack of cross resistance and lack of actiity towards other bacteria points 
towards a novel mechanism of action and a target not found in all bacteria. 
In summary, novel 8-aza-, 7-deaza- 9-deaza and 8-aza-7-deazapurines have been synthesized and 
their biological activities have been compared with those of known antimycobacterial purines with 
similar substitution patterns. It was found that the purine N-9 is important for activity, since the 9-
deazapurines studied were only weak inhibitors of Mtb in the MABA. The purine C-8 may be 
exchanged with nitrogen without significant loss of activity and removal of the purine N-7 results in 
substantially improved growth inhibition. The best results were obtained for some of the 7-
deazapurines with MIC in the MABA comparable with rifampicin. The compounds studied were 
generally of low toxicity towards mammalian (VERO) cells and essentially inactive against other 
bacteria (S. aureus, E. coli). Unfortunately, the compounds studied were not found to be very active 
against Mtb isolates in NRP. 
Experimental 
The 1H NMR spectra were recorded at 500 MHz with a Bruker Avance DRX 500 instrument, at 300 
MHz with a Bruker Avance DPX 300 instrument, or at 200 MHz with a Bruker Avance DPX 200 
or a Varian Gemini instrument. The decoupled 13C NMR spectra were recorded at 125, 75 or 50 
MHz using instruments mentioned above. Mass spectra under electron impact conditions were 
recorded with a VG Prospec instrument at 70 eV ionizing voltage, and are presented as m/z (% rel. 
int.). Elemental analyses were performed by Ilse Beetz Mikroanalytisches Laboratorium, Kronach, 
Germany, or School of Chemistry, University of Birmingham, UK. Melting points were determined 
with a C. Reichert melting point apparatus or a Büchi Melting Point B-545 apparatus and are 
uncorrected. Triethylamine, DMF and CH2Cl2 were distilled from CaH2 and stored over molecular 
sieves (3 Å). THF and anisole and diethyl ether were distilled from Na/benzophenone. Alternatively 
dry THF DMF, Et2O and CH2Cl2 were obtained from a solvent purification system, MB SPS-800 
from MBraun. Silica gel for flash chromatography was purchased from Merck, Darmstadt, 
Germany (Merck No. 09385). All other reagents were commercially available and used as received. 
Compounds synthesized by literature procedures: 5-Amino-4-chloro-6-(4-
methoxybenzylamino)pyrimidine (3),3d 4-(2-furyl)-1-(4-methoxybenzyl)-1H-pyrazolo[3,4-
d]pyrimidine (6).3a Activities against S. aureus,17 E. coli17 and VERO cells1 were determined as 
reported before. 
Antimycobacterial data. 
Minimum inhibitory concentrations (MIC) against replicating and non-replicating cultures of 
Mycobacterium tuberculosis were determined using the microplate Alamar Blue assay (MABA)14 
and low oxygen recovery assay (LORA),16 respectively. The former was determined against M. 
tuberculosis H37Rv ATCC 27294 (American Type Culture Collection) as well as drug-resistant Mtb 
strains following 7 days incubation with test samples. The latter was determined against low 
oxygen adapated M. tuberculosis H37Rv luxAB carrying a luciferase reporter gene following 10 
days incubation under low oxygen followed by 28 hours of normoxic recovery. Both assays were 
conducted in microplate format in 7H12 medium.14b The MIC was defined as the lowest 
concentration effecting a reduction of ≥90% in fluorescence (MABA) or luminescence (LORA) 
relative to untreated controls.  
 7-Chloro-[3-(4-methoxybenzylamino)]-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4). A mixture of 5-
amino-4-chloro-6-(4-methoxybenzylamino)pyrimidine 5 (670 mg, 2.53 mmol), AcOH (50% in 
water, 12 mL) and NaNO2 (192 mg, 2.78 mmol) in dichloromethane (12 mL) was stirred at ambient 
temperature under N2-atm. for 30 min, diluted with dichloromethane (20 mL), washed with water 
(10 mL) and brine (10 mL), dried (MgSO4) and evaporated in vacuo. The product was purified by 
flash chromatography on silica gel eluting with dichoromethane; yield 562 mg (81%), mp 110-112 
oC, off-white powdery crystals. 1H NMR (CDCl3, 200 MHz) δ 3.75 (s, 3H, OCH3), 5.81 (s, 2H, 
CH2), 6.85 (d, J = 8.4 Hz, 2H, Ar), 7.42 (d, J = 8.4 Hz, 2H, Ar), 8.90 (s, 1H, H-5); 13C NMR 
(CDCl3, 50 MHz) δ 51.0 (CH2), 55.3 (OCH3), 114.3 (CH in Ar), 125.8 (C-1 in Ar), 130.0 (CH in 
Ar), 134.1 (C-7a), 149.4 (C-3a / C-7), 154.0 (C-3a / C-7), 155.3 (C-5), 159.9 (C-4 in Ar); MS EI 
m/z (rel. %) 277 / 275 (12 / 36, M+), 248 (39), 246 (92), 234 (6), 232 (18), 218 (7), 216 (22), 134 
(13), 122 (9), 121 (199); HRMS Found 275.0582, calcd. for C12H10ClN5O 275.0574. 
7-(2-Furyl)-[3-(4-methoxybenzylamino)]-3H-[1,2,3]triazolo[4,5-d]pyrimidine (5). A mixture of 
7-chloro-[3-(4-methoxybenzylamino)]-3H-[1,2,3]triazolo[4,5-d]pyrimidine 4 (278 mg, 1.00 mmol), 
2-furyl(tributyl)tin (0.48 mL, 1.5 mmol) and (Ph3P)2PdCl2 (36 mg. 0.050 mmol) in DMF (4 mL) 
was stirred at 90 oC under N2-atm. for 4 h, and evaporated in vacuo. KF in MeOH (sat. sol., 10 mL) 
was added to the residue and the mixture stirred for 18 h. The product was purified by flash 
chromatography on silica gel eluting with EtOAc-hexane (1:2) followed by EtOAc-hexane (1:1) 
and finally pure EtOAc; yield 275 mg (90%), mp 166-168 oC, colorless powdery crystals. 1H NMR 
(CDCl3, 200 MHz) δ 3.75 (s, 3H, OCH3), 5.81 (s, 2H, CH2), 6.72 (dd, J = 3.6 and 1.8 Hz, 1H, 
furyl), 6.84 (d, J = 8.6 Hz, 2H, Ar), 7.43 (d, J = 8.6 Hz, 2H, Ar), 7.82 (br s, 1H, furyl),) 8.11 (br d, J 
= 3.6 Hz, 1H, furyl), 9.07 (s, 1H, H-5); 13C NMR (CDCl3, 50 MHz) δ 50.1 (CH2), 55.0 (OCH3), 
113.1 (CH in furyl), 114.0 (CH in Ar), 120.3 (CH in furyl), 126.3 (C-1 in Ar), 129.7 (CH in Ar), 
130.3 (C-7a), 147.2 (CH in furyl) 147.7 (C-3a / C-7 / C-2 in furyl), 148.4 (C-3a / C-7 / C-2 in 
furyl), 149.1 (C-3a / C-7 / C-2 in furyl), 155.9 (C-5), 159.5 (C-4 in Ar); MS EI m/z (rel. %) 307 (30, 
M+), 279 (26), 278 (82), 264 (15), 250 (17), 159 (7), 146 (9), 121 (100); HRMS Found 307.1065, 
calcd. for C16H13N5O2 307.1069. Anal. Found C, 62.29; H, 4.38; N, 22.47. C16H13N5O2 requires C, 
62.53; H, 4.26; N, 22.79%. 
4-Chloro-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (8a). A mixture of 4-chloro-7-
deazapurine 7a (618 mg, 3.90 mmol) and K2CO3 (1.62 g, 11.7 mmol, oven-dried at 110 oC for 5h) 
in DMF (20 mL) was stirred at ambient temperature under N2-atm, for 30 min, before 4-
methoxybenzyl chloride (1.00 mL, 7.80 mmol) was added. The resulting reaction mixture was 
stirred at ambient temperature for 24 h and poured into water (200 mL). The aqueous phase was 
extracted with EtOAc (2 × 150 mL). The combined organic layers were washed with water (100 
mL) and brine (100 mL), dried (MgSO4) and evaporated in vacuo. The product was purified by 
flash chromatography on silica gel eluting with hexane followed by EtOAc-hexane (1:4); yield 865 
mg (81%), colorless wax. 1H NMR (CDCl3, 300 MHz) δ 3.76 (s, 3H, OCH3), 5.37 (s, 2H, CH2), 
6.58 (d, J = 3.6 Hz, 1H, H-5), 6.84 (d, J = 8.7 Hz, 2H, Ar), 7.15-7.18 (m, 3H, Ar and H-6), 8.66 (s, 
1H, H-2); 13C NMR (CDCl3, 75 MHz) δ 48.0 (CH2), 55.3 (CH3), 99.9 (C-5), 114.3 (CH in Ar), 
117.5 (C-4a), 128.2 (C-1 in Ar), 129.0 (C-6), 129.2 (CH in Ar), 150.7 (C-2), 151.0 (C-4 / C-7a), 
152.0 (C-4 / C-7a), 159.5 (C-4 in Ar); MS EI m/z (rel. %) 275 / 273 (14 / 38, M+), 154 (14), 122 
(16), 121 (100), 91 (6), 90 (2), 98 (3), 78 (13), 77 (9); HRMS Found 273.0668, calcd. for 
C14H12ClN3O 273.0669.   
2,4-Dichloro-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (8b). The title compound was 
synthesized from 2,4-7-deazapurine 7b (1.25 g, 6.65 mmol) following the procedure for synthesis 
of compound 8a. The product was purified by flash chromatography on silica gel eluting with 
EtOAc-hexane (1:9); yield 1.85g, (90%), mp 103-105 oC, colorless crystalline solid. 1H NMR 
(CDCl3, 300 MHz) δ 3.77 (s, 3H, OCH3), 5.31 (s, 2H, CH2), 6.56 (d, J = 3.6 Hz, 1H, H-5), 6.85 (d, 
J = 8.6 Hz, 2H, Ar), 7.12 (d, J = 3.6 Hz, 1H, H-6), 7.17 (d, J = 8.6 Hz, 2H, Ar); 13C NMR (CDCl3, 
75 MHz) δ 48.1 (CH2), 55.3 (CH3), 100.3 (C-5), 114.4 (CH in Ar), 116.3 (C-4a), 127.6 (C-1 in Ar), 
129.4 (CH in Ar and C-6), 152.0 (2 × C, C-2 / C-4 / C-7a), 152.6 (C-2 / C-4 / C-7a), 159.6 (C-4 in 
Ar); MS EI m/z (rel. %) 309 / 307 (6 / 10, M+), 122 (9), 121 (100), 91 (3), 90 (1), 78 (7), 77 (5); 
HRMS Found 307.0278, calcd. for C14H11Cl2N3O 307.0279.  
4-(2-Furyl)-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (9a). The compound was 
synthesized by Stille coupling between compound 8a (277 mg, 1.01 mmol) and 2-furyl(tributyl)tin 
(0.48 mL, 1.5 mmol) following the procedure for synthesis of compound 5. The product was 
purified by flash chromatography on silica gel eluting with EtOAc-hexane (2:3); yield 280 mg 
(92%), mp 130-131 oC, colorless small needles. 1H NMR (CDCl3, 200 MHz) δ 3.76 (s, 3H, OCH3), 
5.39 (s, 2H, CH2), 6.61 (dd, J = 3.2 and 1.6 Hz, 1H, furyl), 6.83 (d, J = 8.6 Hz, 2H, Ar), 6.99 (d, J = 
3.6 Hz, 1H, H-5), 7.14-7.19 (m, 3H, Ar and H-6), 7.38 (br d, J = 3.2 Hz, 1H, furyl), 7.68 (br s, 1H, 
furyl), 8.87 (s, 1H, H-2); 13C NMR (CDCl3, 50 MHz) δ 47.3 (CH2), 55.2 (CH3), 101.1 (C-5), 112.1 
(CH in furyl), 112.6 (CH in furyl), 112.8 (C-4a), 114.1 (CH in Ar), 128.5 (C-6), 128.7 (C-1 in Ar), 
128.9 (CH in Ar), 144.8 (CH in furyl), 147.1 (C in furyl), 151.3 (C-2), 151.8 (C-4 / C-7a), 153.2 (C-
4 / C-7a), 159.0 (C-4 in Ar); MS EI m/z (rel. %) 305 (59, M+), 290 (3), 198 (2), 185 (7), 184 (4), 
157 (4), 156 (3), 153 (2), 129 (4), 122 (14), 121 (100); HRMS Found 305.1160, calcd. for 
C18H15N3O2 305.1164; Anal. Found C, 70.53, H, 5.29; N, 13.48. C18H15N3O2 requires C, 70.81; H, 
4.95; N, 13.76%. 
7-(4-Methoxybenzyl)-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine (9b). The compound was 
synthesized by Stille coupling between compound 8a (740 mg, 2.70 mmol) and 2-
thienyl(tributyl)tin (1.2 mL, 3.5 mmol) following the procedure for synthesis of compound 5. The 
product was purified by flash chromatography on silica gel eluting with EtOAc-hexane (1:3); yield 
850 mg (96 %), mp 109-110 oC, colorless crystals. 1H NMR (CDCl3, 500 MHz) δ 3.77 (s, 3H, 
OCH3), 5.40 (s, 2H, CH2), 6.84 (d, J = 8.7 Hz, 2H, Ar), 6.87 (d, J = 3.5 Hz, 1H, H-5), 7.19 (d, J = 
8.7 Hz, 2H, Ar), 7.21 (m, 2H, H-6 and 1H in thienyl), 7.55 (d, J = 4.9 Hz, 1H, thienyl), 8.02 (br s, 
1H, thienyl), 8.88 (s, 1H, H-2); 13C NMR (CDCl3, 75 MHz) δ 47.5 (CH2), 55.3 (CH3), 100.4 (C-5), 
113.3 (C-4a), 114.2 (CH in Ar), 128.3-129.5 (3 × CH in thienyl, C-6 and C-1 in Ar), 129.1(CH in 
Ar), 142.8 (C-2 in thienyl), 151.0 (C-2), 151.2 (C-4 / C-7a), 151.8 (C-4 / C-7a), 159.4 (C-4 in Ar); 
MS EI m/z (rel. %) 321 (39, M+), 306 (1), 214 (1), 200 (1), 122 (9), 121 (100), 78 (7), 77 (6); 
HRMS Found 321.0940, calcd. for C18H15N3OS 321.0936. Anal. Found C, 66.95, H, 4.98; N, 12.82. 
C18H15N3OS requires C, 67.27; H, 4.70; N, 13.07%.  
2-Chloro-4-(2-furyl)-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (9c). A mixture of 
tris(dibenzylideneacetone)dipalladium chloroform adduct (16 mg, 0.015 mol)  and tri(2-
furyl)phosphine (26 mg, 0.11 mmol) in DMF (2 mL) was stirred at ambient temperature under N2-
atm. for 15 min, before compound 8b (155 mg, 0.500 mmol) in DMF (2 mL) and 2-
furyl(tributyl)tin (0.20 mL, 0.60 mmol) were added. The resulting mixture was stirred for 8 h at 50 
oC and evaporated in vacuo. A sat. solution of potassium fluoride in methanol was added to the 
residue and the mixture was stirred overnight and evaporated in vacuo together with a small amount 
of silica gel. The residue was added on top of a chromatography column and the product was 
isolated by flash chromatography on silica eluting with EtOAc-isohexane (1:12) followed by 
EtOAc-isohexane (1:6) and EtOAc-isohexane (1:3); yield 145 mg (85%), mp 128-130 oC, colorless 
crystalline solid. 1H NMR (CDCl3, 300 MHz) δ 3.77 (s, 3H, OCH3), 5.33 (s, 2H, CH2), 6.60 (dd, J 
= 3.6 and 1.6 Hz, 1H, H-4 in furyl), 6.84 (d, J = 8.7 Hz, 2H, Ar), 6.96 (d, J = 3.6 Hz, 1H, H-5), 7.11 
(d, J = 3.6 Hz, 1H, H-6), 7.18 (d, J = 8.8 Hz, 2H, Ar), 7.45 (dd, J = 3.6 and 0.5 Hz, 1H, H-3 in 
furyl), 7.68 (dd, J = 1.7 and 0.6 Hz, 1H, H-5 in furyl); 13C NMR (CDCl3, 75 MHz) δ 47.5 (CH2), 
55.3 (CH3), 101.9 (C-5), 111.7 (C-4a), 112.4 (C-4 in furyl), 114.3 (CH in Ar and C-3 in furyl), 
128.3 (C-1 in Ar), 129.1 (C-6), 129.3 (CH in Ar), 145.6 (C-5 in furyl), 148.8 (C-2), 152.3 (C-2 in 
furyl), 153.5 (C-4 / C-7a), 153.4 (C-4 / C-7a), 159.4 (C-4 in Ar); MS EI m/z (rel. %) 341 / 339 (7 / 
21, M+), 218 (1), 122 ( 9), 121 (100), 91 (3), 89 (1), 78 (6), 77 (6); HRMS Found 339.0777, calcd. 
for C18H14ClN3O2 339.0775. Anal. Found C, 63.76, H, 4.38; N, 12.11. C18H14ClN3O2 requires C, 
63.63; H, 4.15; N, 12.37%.  
2-Chloro-7-(4-methoxybenzyl)-4-(2-thienyl)-7H-pyrrolo[2,3-d]pyrimidine (9d). The compound 
was synthesized by Stille coupling between compound 8b (800 mg, 2.60 mmol) and 2-
thienyl(tributyl)tin (0.10 mL, 3.1 mmol) and PdCl2(PPh3)2 (5.5 mg, 0.078 mmol) as catalyst, 
otherwise following the procedure for synthesis of compound 9c. The product was isolated by flash 
chromatography on silica eluting with EtOAc-isohexane (1:6) followed by EtOAc-isohexane (1:3); 
yellow crystals, yield 550 mg (60%), mp 124-126 oC, colorless crystalline solid. 1H NMR (CDCl3, 
300 MHz) δ 3.77 (s, 3H, OCH3), 5.34 (s, 2H, CH2), 6.82-6.86 (m, 3H, Ar and H-5), 7.13 (d, J = 3.7 
Hz, 1H, H-6), 7.17-7.21 (m, 3H, Ar and 1H in thienyl), 7.57 (dd, J = 5.0 and 1.0 Hz, 1H, thienyl), 
7.98 (dd, J = 3.6 and 1.0 Hz, 1H, thienyl); 13C NMR (CDCl3, 75 MHz) δ 47.6 (CH2), 55.3 (CH3), 
100.8 (C-5), 112.2 (C-4a), 114.3 (CH in Ar), 128.2 (CH in thienyl / C-1 in Ar), 128.3 (CH in 
thienyl / C-1 in Ar), 129.2 (C-6 / CH in thienyl), 129.4 (CH in Ar), 129.7 (C-6 / CH in thienyl), 
130.4 (CH in thienyl), 141.4 (C-2 in thienyl), 152.9 (C-2 / C-4 / C-7a), 153.3 (C-2 / C-4 / C-7a), 
153.4 (C-2 / C-4 / C-7a), 159.5 (C-4 in Ar); MS EI m/z (rel. %) 357 / 355 (7 / 19, M+), 307 (2), 121 
(100), 91 (5), 78 (6), 77 (6); HRMS Found 355.0551, calcd. for C18H14ClN3OS 355.0546. Anal. 
Found C, 60.53, H, 4.31; N, 11.64. C18H14ClN3OS requires C, 60.76; H, 3.97; N, 11.81%.  
4-(2-Furyl)-2-methoxy-7-(4-methoxybenzyl)-7H-pyrrolo[2,3-d]pyrimidine (9e). A solution of 
9c (150 mg, 0.440 mmol) in a freshly prepared solution of sodium methoxide in methanol (ca. 1.5 
M, 15 mL) was heated at reflux under N2-atm. for 24 h. The reaction mixture was cooled to ambient 
temperature and quenched with sat. aq. NH4Cl (30 mL). The resulting mixture was evaporated in 
vacuo, the suspension obtained was dissolved in EtOAc (30 mL) and washed with sat. aq. NH4Cl 
(20 mL). The aqueous phase was extracted with EtOAc (3 × 20 mL). The combined organic phase 
was dried (MgSO4) and concentrated in vacuo. The product was purified by flash chromatography 
eluting with EtOAc (1:4); yield 125 mg (84%), mp 92-94 oC, off-white crystalline solid. 1H NMR 
(Me2CO-d6, 300 MHz) δ 3.75 (s, 3H, OCH3), 4.02 (s, 3H, OCH3), 5.34 (s, 2H, CH2), 6.69 (dd, J = 
3.5 and 1.76 Hz, 1H, H-4 in furyl), 6.87 (d, J = 8.7 Hz, 2H, Ar), 6.92 (d, J = 3.6 Hz, H-5), 7.30-7.34 
(m, 3H, H-6 and 2H in Ar), 7.39 (dd, J = 3.5 and 1.6 Hz, 1H, H-3 in furyl), 7.87 (dd, J = 1.7 and 
0.74 Hz, H-5 in furyl); 13C NMR (CDCl3, 75 MHz) δ 47.7 (CH2), 54.6 (CH3), 55.5 (CH3), 101.7 (C-
5), 109.5 (C-4a), 113.0 (C-4 in furyl), 113.5 (C-3 in furyl), 114.8 (CH in Ar), 128.7 (C-6), 130.1 (C-
H in Ar), 130.6 (C-1 in Ar), 146.3 (C-5 in furyl), 149.0 (C-7a), 154.5 (C-2 in furyl), 155.2 (C-4), 
160.3 (C-4 in Ar), 162.9 (C-2); MS EI m/z (rel. %) 335 (56, M+), 299 (6), 122 (8), 121 (100); 
HRMS Found 335.1269, cacld. for C19H15N3O3 335.1270; Anal. Found C, 67.85, H, 5.00. 
C19H15N3O3 requires C, 68.05; H, 5.11%.  
4-Chloro-7-bromo-5H-pyrrolo[3,2-d]pyrimidine (11).18 N-Bromosuccinimide (0.30 g, 1.7 mmol) 
was added in small portions to a well stirred solution of 10 (0.20 g, 1.3 mmol) in THF (10 mL) 
under N2-atm., the resulting reaction mixture was stirred at ambient temperature for 2 h. A small 
amount of silica gel was added and the mixture was evaporated. The residue was added on top of a 
silica gel flash chromatography column, and the product was isolated after elution with CH2Cl2 
followed by 5% MeOH in CH2Cl2; yield 190 mg (63%), mp 230-232 oC, colorless crystalline solid. 
1H NMR (DMSO-d6, 300 MHz) δ 8.23 (s, 1H, H-6), 8.71 (s, 1H, H-2), 12.9 (s, 1H, NH); 13C NMR 
(DMSO-d6, 75 MHz) δ 89.7 (C-7), 123.9 (C-4a), 113.9 (C-6), 142.5 (C-4), 147.5 (C-7a), 149.9 (C-
2); MS EI m/z (rel. %) 233 / 231 (100 / 76, M+), 198 (50), 196 (50), 117 (24); HRMS Found 
230.9199, calcd. for C6H3BrClN3 230.9199. Anal. Found C, 31.21, H, 1.20; N, 17.93. C6H3BrClN3 
requires C, 31.00; H, 1.30; N, 18.08%. 
4-Chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine (12). NaH (ca. 60% in oil, 260 mg, ca. 6.5 
mmol) was added in small portions to a stirring mixture of 4-chloro-5H-pyrrolo[3,2-d]pyrimidine 
10 (500 mg, 3.25 mmol) in dry DMF (10 mL) at 0 oC under N2-atm. The resulting mixture was 
stirred for 1 h at 0 oC before iodomethane (0.46 mL, 3.5 mmol) was added drop wise. The reaction 
mixture was allowed to gradually reach ambient temperature over 2 h and again cooled to 0 oC. 
Acetic acid (1 mL) was added and the resulting suspension was stirred for 15 min, before the 
solvents were evaporated in vacuo. The residue was dissolved in EtOAc (50 mL) and washed with 
sat. aq. NaHCO3 (25 mL) and water (25 mL). The aq. phases were extracted with EtOAc (25 mL) 
and the combined EtOAc extracts were dried (MgSO4) and evaporated in vacuo. The product was 
used without further purification; yield 508 mg (93%), off-white solid. 1H NMR (CD3COD, 200 
MHz) δ 4.17 (s, 3H, CH3), 6.66 (d, J = 3.2 Hz, 1H, H-7), 7.78 (d, J = 3.2 Hz, 1H, H-6), 8.54 (s, 1H, 
H-2); MS EI m/z (rel. %) 169 / 167 (28/83, M+), 132 (100). Spectral data are in good agreement 
with those reported before.19  
7-Bromo-4-chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine (13a).  
Method A: NaH (27 mg, ca. 0.68 mmol, ca. 60% in oil,) was added in small portions to a well 
stirred solution of 11 (80 mg, 0.34 mmol) in dry DMF (2 mL) at 0 °C under N2-atm. The reaction 
mixture was stirred for 1 h at 0 °C before iodomethane (0.021 mL, 0.34 mmol) was added 
dropwise. The reaction mixture was allowed to gradually reach ambient temperature over 1.5 h and 
subsequently cooled to 0 °C. Glacial acetic acid (0.1 mL) was added and resulting suspension was 
stirred for 10 min, before the solvents were evaporated in vacuo. The residue was dissolved in 
EtOAc (40 mL), washed with sat. aq. NaHCO3 (40 mL) and brine (30 mL), dried (MgSO4) and 
evaporated in vacuo. The product was purified by flash chromatography on silica gel eluting with 
CH2Cl2 followed by MeOH-CH2Cl2 (1:199); yield 74 mg (88%), mp 200-201 oC, colorless crystals. 
1H NMR (CDCl3, 200 MHz) δ 4.15 (s, 3H, CH3), 7.45 (s, 1H, H-6), 8.74 (s, 1H, H-2); 13C NMR 
(CDCl3, 175 MHz) δ 36.5 (CH3), 87.8 (C-7), 123.5 (C-4a / C-7a), 138.3 (C-6), 142.1 (C-4a / C-7a), 
148.1 (C-4), 149.6 (C-2); MS EI m/z (rel. %) 249 / 247 / 245 (25 / 100 / 77, M+), 212 (49), 210 (51), 
131 (22); HRMS Found 244.9359, calcd. for C7H5BrClN3 244.9355. Anal. Found C, 34.10, H, 1.99, 
N, 17.11. C7H5BrClN3 requires C, 34.11, H, 2.04, N, 17.05%. 
Method B: NBS (436 mg, 2.45 mmol) was added in small portions to a stirring mixture of 4-chloro-
5-methyl-5H-pyrrolo[3,2-d]pyrimidine 12 (410 mg, 2.45 mmol) in dry dichloromethane (10 mL) at 
ambient temperature under N2-atm. The resulting mixture was stirred for 2 h, diluted with 
dichloromethane (10 mL) and washed with water (2 × 10 mL) and brine (10 mL), dried MgSO4) 
and evaporated. The product was purified by flash chromatography on silica gel eluting with 
MeOH-CH2Cl2 (1:99); yield 460 mg (76%). 
7-Bromo-4-chloro-5-[(triisopropylsilyloxy)methyl]-5H-pyrrolo[3,2-d]pyrimidine (13b). NaH 
(51 mg, ca. 1.3 mmol, ca. 60% in oil) was added to a solution of 11 (250 mg, 1.07 mmol) in DMF 
(4 mL) at 0 oC. The reaction mixture was stirred at this temperature under N2-atm. for 1h, before 
(triisopropylsilyloxy)methyl chloride (0.30 mL, 1.3 mmol) was added dropwise. The reaction 
mixture was allowed to reach ambient temperature over 2 h before it was cooled to 0 oC and few 
drops of water were added. The solvent was evaporated in vacuo, the residue was suspended in 
water (40 mL) and was extracted with EtOAc (3 × 50 mL). The combined organic layers were 
washed with brine (100 mL), dried (MgSO4) and evaporated in vacuo. The product was purified by 
flash chromatography on silica gel eluting with EtOAc-hexane (1:9) followed by EtOAc-hexane 
(1:4); yield 380 mg (84%), mp 164-166 oC, colorless crystals. 1H NMR (CDCl3, 300 MHz) δ 1.02 
(d, J = 6.3 Hz, 18H, 6 × CH3), 1.11-1.18 (m, 3H, 3 × CH in i-Pr), 6.00 (s, 2H, CH2), 7.68 (s, 1H, H-
6), 8.79 (s, 1H, H-2); 13C NMR (CDCl3, 75 MHz) δ 11.9 (3 × CH in i-Pr), 17.8 (6 × CH3), 72.3 
(CH2), 91.7 (C-7), 123.4 (C-4a), 134.6 (C-6), 142.9 (C-7a), 149.8 (C-4), 150.7 (C-2); MS ESI 422 / 
420 / 418 [M+H]; HRMS Found 418.0722, calcd. for C16H25BrClN3OSi+H 418.0712. Anal. Found 
C, 45.95, H, 6,17; N, 9.86. C16H25BrClN3OSi requires C, 45.88; H, 6.02; N, 10.03%.  
4-Chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidine-7-carbaldehyde (14a). To a suspension of 
compound 13a  (0.175 g, 0.700 mmol) in dry diethyl ether (8 mL) and anisole (3 mL) was added n-
BuLi (0.63 mL, 0.91 mmol, 1.44 M sol.) at -78 oC under N2-atm. The reaction mixture was stirred 
at -78 oC for 40 min, before DMF (0.27 mL, 3.5 mmol) was added drop wise. The reaction mixture 
was stirred at -78 oC for an additional 1 h, was quenched by the addition of of water (2 mL) and 
diluted with EtOAc (20 mL). The mixture was washed with water (20 mL) and the aqueous phase 
was extracted with EtOAc (2 × 15 mL). The combined organic extracts were dried (MgSO4) and 
evaporated in vacuo and the product was isolated by flash chromatography eluting with CH2Cl2 
followed by MeOH-CH2Cl2 (1:99); yield 115 mg (84%), mp 212-213 oC, off-white crystals. 1H 
NMR (Me2CO-d6, 300 MHz) δ 4.31 (s, 3H, CH3), 8.46 (s, 1H, H-6), 8.76 (s, 1H, H-2), 10.26 (s, 1H, 
CHO); 13C NMR (Me2CO-d6, 75 MHz) δ 37.9 (CH3), 116.9 (C-7), 142.7 (C-6), 144.2 (C-4), 151.5 
(C-7a), 152.3 (C-2), 183.4 (CHO), C-4a was hidden; MS EI m/z (rel. %) 197 / 195 (4 / 13 M+), 169 
(32), 167 (100), 166 (39), 158 (8); HRMS Found 195.0194, cacld. for C8H6ClN3O 195.0199. Anal. 
Found C, 49.20; H, 2.95; N, 21.46. C8H6ClN3O requires C, 49.12; H, 3.09; N, 21.48%. Compound 
14a was also synthesized from the iodide 13c (130 mg, 0.44 mmol) otherwise following the same 
procedure; yield 59 mg (69%). 
4-Chloro-5-[(triisopropylsilyloxy)methyl]-5H-pyrrolo[3,2-d]pyrimidine-7-carbaldehyde (14b). 
The product was synthesized from compound 13b (240 mg, 0.570 mmol) as described for the 
synthesis of compound 14a above and the product was isolated by flash chromatography eluting 
with EtOAc-hexane (1:9) followed by EtOAc-hexane (1:4); yield 180 mg, (86%), mp 140-141 oC, 
colorless crystals. 1H NMR (Me2CO-d6, 300 MHz) δ 1.07 (d, J = 7.0 Hz, 18H, 6 × CH3), 1.19-1.26 
(m, 3H, 3 × CH in i-Pr), 6.27 (s, 2H, CH2), 8.70 (s, 1H, H-6), 8.81 (s, 1H, H-2), 10.31 (s, 1H, 
CHO); 13C NMR (Me2CO-d6, 75 MHz) δ 12.6 (3 × CH in i-Pr), 18.1 (6 × CH3), 74.0 (CH2), 117.7 
(C-7), 125.1 (C-4a), 140.2 (C-6), 144.2 (C-4), 152.1 (C-7a), 152.8 (C-2), 183.8 (CHO); MS ESI 
370 / 368 [M+H]; HRMS Found 368.1568, calcd. for C17H26ClN3O2Si+H 368.1556. Anal. Found 
C, 55.61, H, 7.16; N, 11.21. C17H26ClN3O2Si requires C, 55.49; H, 7.12; N, 11.42%. 
 (4-Chloro-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl)(4-methoxyphenyl)methanone (15a). 
LiCl (224 mg, 5.30 mmol) was dried under high vacuum for 1 h and then at 110 oC for 30 min. The 
flask fitted with air condenser was cooled under nitrogen and magnesium turnings (128 mg, 5.30 
mmol) were introduced. A crystal of iodine and THF (7.5 mL) was added and the reaction mixture 
stirred vigorously. 4-Bromoanisol (0.67 mL, 5.3 mmol) was added slowly over a period of 10 min. 
The resulting reaction mixture was stirred at ambient temperature until the disappearance of 
magnesium (ca. 1 h). The resulting Grignard reagent was titrated against cyclohexanol using 1,10-
phenanthroline as indicator. To a solution of compound 14a (170 mg, 0.870 mmol) was added the 
4-methoxyphenylmagnesium bromide-LiCl solution described above (2.2 mL, 1.0 mmol, 0.47 M in 
THF) at 0 oC under N2-atm. The reaction mixture was stirred at 0 oC for 20 min, before 
benzaldehyde (0.13 mL, 1.3 mmol) was added. The resulting mixture was stirred at ambient 
temperature under N2-atm. for 40 h, a small amount of silica gel was added and the mixture 
evaporated. The residue was added on to of a flash chromatography column and the product eluted 
with a MeOH-CH2Cl2 mixture gradually increasing the amount of MeOH from 0.5% to 1%; yield 
198 mg (74%), mp 199-200 oC, colorless crystals. 1H NMR (CDCl3, 300 MHz) δ 3.84 (s, 3H, 
OCH3), 4.19 (s, 3H, NCH3), 6.91 (d J = 8.8 Hz, 2H, Ar), 7.90 (d J = 8.8 Hz, 2H, Ar), 7.96 (s, 1H, 
H-6), 8.75 (s, 1H, H-2); 13C NMR (CDCl3, 75 MHz) δ 37.5 (NCH3), 55.4 (OCH3), 133.5 (CH in 
Ar), 116.4 (C-7), 124.9 (C-4a), 131.3 (C-1 in Ar), 132.2 (CH in Ar), 142.5 (C-6), 143.5 (C-4), 
149.4 (C-7a), 151.4 (C-2), 163.4 (C-4 in Ar), 187.3 (CO); MS EI m/z (rel. %) 303 / 301 (29 / 86 
M+), 274 (37), 272 (100), 194 (36), 135 (21); HRMS Found 301.0617, cacld. for C15H12ClN3O2 
301.0618.  
{4-Chloro-5-[(triisopropylsilyloxy)methyl]-5H-pyrrolo[3,2-d]pyrimidin-7-yl}(4-
methoxyphenyl)methanone (15b). The compound was synthesized from 14b (260 mg, 0.700 
mmol) following the procedure for the synthesis of 15a above. The product was isolated by flash 
chromatography eluting with EtOAc-hexane (1:9) followed by EtOAc-hexane (1:4); yield 214 mg 
(64%), mp 135-138 oC, off-white crystals. 1H NMR (CDCl3, 300 MHz) δ 1.05 (d, J = 6.5 Hz 18H, 6 
× CH3), 1.13-1.20 (m, 3H, 3 × CH in i-Pr), 3.89 (s, 3H, OCH3), 6.08 (s, 2H, CH2), 6.95 (d J = 8.9 
Hz, 2H, Ar), 7.95 (d J = 8.9 Hz, 2H, Ar), 8.19 (s, 1H, H-6), 8.83 (s, 1H, H-2); 13C NMR (CDCl3, 75 
MHz) δ 12.5 (3 × CH in i-Pr), 17.8 (6 × CH3), 55.5 (OCH3), 72.9 (CH2), 113.6 (CH in Ar), 117.2 
(C-7), 124.0 (C-4a), 131.1 (C-1 in Ar), 132.3 (CH in Ar), 140.3 (C-6), 143.3 (C-4), 150.3 (C-7a), 
151.7 (C-2), 163.5 (C-4 in Ar), 187.4 (CO); MS EI m/z (rel. %) 473 (7, M+), 432 (41), 430 (100), 
402 (21), 400 (54), 137 (21), 135 (26); HRMS Found 473.1901, cacld. for C24H32ClN3O3Si 
473.1901. Anal. Found C, 60.69, H, 6.80; N, 8.60. C24H32ClN3O3Si requires C, 60.80; H, 6.80; N, 
8.86%.  
 [4-(2-Furyl)-5-methyl-5H-pyrrolo[3,2-d]pyrimidin-7-yl](4-methoxyphenyl)methanone (16a). 
The compound was synthesized by Stille coupling between compound 15a (90 mg, 0.29 mmol) and 
2-furyl(tributyl)tin (0.110 mL, 0.350 mmol) following the procedure for synthesis of compound 5. 
The product was purified by flash chromatography on silica gel eluting with CH2Cl2, MeOH-
CH2Cl2 (1:199), and finally MeOH-CH2Cl2 (1:99); yield 70 mg (72%), mp 252-254 oC, yellow 
crystals. 1H NMR (CDCl3, 300 MHz) δ 3.84 (s, 3H, OCH3), 4.01 (s, 3H, NCH3), 6.64 (dd, J = 3.5 
and 1.8 Hz 1H, H-4 in furyl), 6.19 (d, J = 8.8 Hz, 2H, Ar), 7.28 (dd, J = 3.5 and 0.8 Hz, 1H, H-3 in 
furyl), 7.67 (br s, 1H, H-5 in furyl), 7.92 (d, J = 8.8 Hz, 2H, Ar), 7.95 (s, 1H, H-6), 9.00 (s, 1H, H-
2); 13C NMR (CDCl3, 75 MHz) δ 38.9 (NCH3), 55.4 (OCH3), 112.6 (C-4 in furyl), 113.4 (CH in 
Ar), 114.3 (C-3 in furyl), 116.0 (C-7), 124.4 (C-4a), 131.4 (C-1 in Ar), 132.1 (CH in Ar), 140.6 (C-
4), 143.3 (C-6), 144.7 (C-5 in furyl), 150.3 (C-7a), 150.5 (C-2 in furyl), 151.6 (C-2), 163.1 (C-4 in 
Ar), 187.7 (CO); MS EI m/z (rel. %) 333 (100 M+), 332 (60), 305 (45), 304 (85), 276 (18); HRMS 
Found 333.1108, cacld. for C19H15N3O3 333.1113. Anal. Found C, 66.70; H, 4.36; N, 12.21. 
C19H15N3O requires C, 68.46; H 4.54; N 12.61%. 
{4-(2-furyl)-5-[(triisopropylsilyloxy)methyl]-5H-pyrrolo[3,2-d]pyrimidin-7-yl}(4-
methoxyphenyl)methanone (16b). A mixture of compound 15b (645 mg, 1.40 mmol), 2-
furyl(tributyl)tin (0.52 mL, 1.6 mmol) and (Ph3P)2PdCl2 (48 mg, 0.070 mmol) in DMF (4 mL) was 
stirred at 90 oC under N2-atm for 18 h, and evaporated in vacuo. The residue was dissolved in 
MeCN (40 mL) and was washed with hexane (5 × 50 mL). Hexane (50 mL) was added to the 
MeCN layer and resulting mixture was stirred at ambient temperature for 1h, the layers were 
separated and the MeCN layer was evaporated in vacuo. The product was isolated by flash 
chromatography eluting with EtOAc-hexane (1:3); yield 450 mg (65%), mp 108-110 oC, off-white 
crystalline solid. 1H NMR (Me2CO-d6, 500 MHz) δ 0.93 (d, J = 7.2 Hz 18H, 6 × CH3), 1.04-1.08 
(m, 3H, 3 × CH in i-Pr), 3.91 (s, 3H, OCH3), 6.28 (s, 2H, CH2), 6.78 (dd, J = 3.5 and 1.8 Hz 1H, H-
4 in furyl), 7.04 (d J = 8.9 Hz, 2H, Ar), 7.38 (dd, J = 3.5 and 0.9 Hz, 1H, H-3 in furyl), 7.95 (m, 3H, 
2H in Ar and H-5 in furyl), 8.54 (s, 1H, H-6), 8.89 (s, 1H, H-2); 13C NMR (Me2CO-d6, 125 MHz) δ 
12.5 (3 × CH in i-Pr), 18.0 (6 × CH3), 55.9 (OCH3), 75.1 (CH2), 113.2 (C-4 in furyl), 114.1 (CH in 
Ar), 114.4 (C-3 in furyl), 117.5 (C-7), 123.5 (C-4a), 132.6 (C-1 in Ar), 132.9 (CH in Ar), 141.8 (C-
4), 142.6 (C-6), 146.2 (C-5 in furyl), 152.0 (C-7a), 152.2 (C-2 and C-2 in furyl), 164.2 (C-4 in Ar), 
187.8 (CO); MS ESI 506 [M+H]; HRMS Found 506.2458, calcd. for C28H35N3O4Si+H 506.2470. 
[4-(2-Furyl)-5H-pyrrolo[3,2-d]pyrimidin-7-yl](4-methoxyphenyl)methanone (16c). A solution 
of compound 16b (225 mg, 0.440 mmol) in a saturated solution of KF in MeOH was stirred at 
ambient temperature for 12 h before few drops of methanolic ammonia were added and resulting 
mixture was stirred for 1 h at ambient temperature. The product was isolated by flash 
chromatography eluting with EtOAc-hexane (1:1) followed by pure EtOAc; yield 120 mg (86%), 
mp 230-233 oC (dec.), pale yellow crystalline solid. 1H NMR (DMSO-d6, 300 MHz) δ 3.85 (s, 3H, 
OCH3), 6.84 (dd, J = 3.5 and 1.7 Hz 1H, H-4 in furyl), 7.06 (d, J = 8.8 Hz, 2H, Ar), 7.52 (d, J = 3.5, 
1H, H-3 in furyl), 7.91 (d, J = 8.8 Hz, 2H, Ar), 8.09 (br s, 1H, H-5 in furyl), 8.33 (s, 1H, H-6), 8.86 
(s, 1H, H-2); 13C NMR (DMSO-d6, 75 MHz) δ 55.5 (OCH3), 112.8 (CH in furyl), 113.1 (CH in 
furyl), 113.5 (CH in Ar), 115.7 (C-7), 121.1 (C-4a), 131.4 (C-1 in Ar), 131.9 (CH in Ar), 139.2 (C-
4), 139.4 (C-6), 146.4 (C-5 in furyl), 148.6 (C-7a), 150.6 (C-2 in furyl), 151.4 (C-2), 162.7 (C-4 in 
Ar), 187.4 (CO); MS EI m/z (rel. %) 319 (100 M+), 290 (70), 261 (17), 160 (9); HRMS Found 
319.0957, calcd. for C18H13N3O3 319.0957. Anal. Found C, 67.55, H, 4.00; N, 12.92. C18H13N3O3 
requires C, 67.71; H, 4.10; N, 13.16%. 
4-(2-Furyl)-7-(4-methoxybenzyl)-5-methyl-5H-pyrrolo[3,2-d]pyrimidine (17). A suspension of 
16a (95 mg, 0.29 mmol) in ethylene glycol (3.0 mL) and hydrazine hydrate (0.28 mL, 5.7 mmol) 
was heated until a clear solution was obtained (ca. 10 min, ca. 70 °C) before crushed NaOH (228 
mg, 5.70 mmol) was introduced. The resulting mixture was heated at 120 °C for 18 h before the 
reaction mixture was cooled to 0 °C and neutralized by dropwise addition of  10% aq. HCl with 
stirring. After complete neutralization, water (20 mL) was added and resulting mixture was 
extracted with EtOAc (5 × 20 mL). The combined organic phases were washed with water (50 mL) 
followed by brine (50 mL), dried (MgSO4) and evaporated in vacuo. The product was purified by 
flash chromatography on silica gel eluting with CH2Cl2, followed by MeOH-CH2Cl2 (1:199) and 
finally MeOH-CH2Cl2 (7:193); yield 65 mg, (71%), mp 114-115 oC, yellow crystalline solid. 1H 
NMR (CDCl3, 200 MHz) δ 3.77 (s, 3H, OCH3), 3.90 (s, 3H, NCH3), 4.12 (s, 2H, CH2), 6.65 (dd, J 
= 3.5 and 1.8 Hz 1H, H-4 in furyl), 6.83 (d, J = 8.7 Hz, 2H, Ar), 7.06 (s, 1H, H-6), 7.24 (d, J = 8.7 
Hz, 2H, Ar),7.32 (br d, J = 3.5 Hz, 1H, H-3 in furyl), 7.66 (dd, J = 1.8 and 0.8 Hz, 1H, H-5 in 
furyl), 8.95 (s, 1H, H-2); 13C NMR (CDCl3, 75 MHz) δ 29.2 (CH2), 38.2 (NCH3), 55.7 (OCH3), 
112.9 (C-4 in furyl), 114.1 (C-3 in furyl), 114.4 (CH in Ar), 116.5 (C-7a), 124.6 (C-4a), 130.4 (CH 
in Ar), 133.4 (C-1 in Ar), 137.3 (C-6), 139.7 (C-4), 144.8 (C-5 in furyl), 149.6 (C-2), 151.4 (C-2 in 
furyl), 158.4 (C-4 in Ar), the signal from C-7 was hidden. MS EI m/z (rel. %) 319 (100, M+), 318 
(28), 304 (88), 288 (5), 160 (8); HRMS Found 319.1325, cacld. for C19H15N3O3 319.1321; Anal. 
Found C, 71.18, H, 5.56; N, 12.69. C19H17N3O2 requires C, 71.46; H, 5.37; N, 13.16%. 
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Legends to Figures and Schemes 
 
Fig. 1. SAR summary for antimycobacterial purines A, structures of some of the most active 
purines (1a-1f), general structures of pyrimidine- B and imidazole analogs C and general structure 
of the target compounds D described in this study. 
 
Fig. 2. Structure of compound 6. 
 
Scheme 1. (a) p-MeO-C6H4-CH2NH2, Et3N, n-BuOH, ∆; (b) NaNO2, AcOH, CH2Cl2, H2O; (c) (2-
Furyl)SnBu3, (Ph3P)2PdCl2; DMF, 90 oC.  
 
Scheme 2. (a) p-MeO-C6H4-CH2Cl, K2CO3, DMF; (b) R = H: (2-Furyl)SnBu3 or (2-Thienyl)SnBu3 
(Ph3P)2PdCl2, DMF, 90 oC; (c) R = Cl: (2-furyl)SnBu3 or (2-thienyl)SnBu3, [(2-Furyl)3P]4Pd or 
(Ph3P)2PdCl2, DMF, 50 oC; (d) MeONa, MeOH, ∆. 
 
Scheme 3. (a) NBS, THF; (b) NaH, MeI, DMF; (c) NaH, TOM-Cl, THF, 0 oC – r.t.; (d) NBS, 
CH2Cl2; (e) 1. n-BuLi, Et2O, anisole, -78 oC, 2. DMF; (f) 1. p-MeO-C6H4-MgBr, LiCl, THF, 0 oC – 
r.t., 2. PhCHO; (g) 1. (2-Furyl)SnBu3, (Ph3P)2PdCl2, DMF, 90 oC; (h) KF, MeOH; (i) NH2NH2, 
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